Compare PEB & DVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PEB | DVAX |
|---|---|---|
| Founded | 2009 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | 2009 | 2004 |
| Metric | PEB | DVAX |
|---|---|---|
| Price | $11.26 | $10.80 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 9 | 4 |
| Target Price | $12.28 | ★ $26.50 |
| AVG Volume (30 Days) | ★ 2.0M | 1.5M |
| Earning Date | 11-05-2025 | 11-05-2025 |
| Dividend Yield | ★ 0.35% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,464,126,000.00 | $330,514,000.00 |
| Revenue This Year | $2.32 | $24.63 |
| Revenue Next Year | $2.42 | $15.85 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 0.99 | ★ 26.73 |
| 52 Week Low | $7.42 | $9.20 |
| 52 Week High | $14.85 | $14.63 |
| Indicator | PEB | DVAX |
|---|---|---|
| Relative Strength Index (RSI) | 56.64 | 48.59 |
| Support Level | $10.67 | $10.71 |
| Resistance Level | $11.71 | $11.00 |
| Average True Range (ATR) | 0.34 | 0.26 |
| MACD | 0.02 | -0.06 |
| Stochastic Oscillator | 61.24 | 22.63 |
Pebblebrook Hotel Trust currently owns upper upscale and luxury hotels with 11,933 rooms across 46 hotels in the United States. Pebblebrook acquired LaSalle Hotel Properties, which owned 10,451 rooms across 41 US hotels, in November 2018, though management has sold many of those hotels over the past few years. Pebblebrook's portfolio consists mostly of independent hotels with no brand affiliations, though the combined company does own and operate some hotels under Marriott, Starwood, InterContinental, Hilton, and Hyatt brands.
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.